Werewolf Therapeutics (HOWL) FCF Margin (2022 - 2026)

Werewolf Therapeutics (HOWL) posted quarterly FCF Margin of 31.57% for Q2 2026, up 100.03% on a QoQ basis from 95833.33% in Q4 2024.

Werewolf Therapeutics (HOWL) FCF Margin (2022 - 2026) Analysis & Trends

Werewolf Therapeutics has reported FCF Margin for 4 years, with the latest figure at 31.57% in Q2 2026.

FCF Margin for Q2 2026 came in at 31.57%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was 143.56% (up 40620310.0% YoY), and the FY2024 annual result was 2970.63%, down 280325.0% from the prior year.
FCF Margin advanced to 31.57% in Q2 2026, from 95833.33% in the prior quarter.
Over five years, FCF Margin peaked at 31.57% in Q2 2026 and troughed at 95833.33% in Q4 2024.
A 4-year average of 9129.87% and a median of 225.49% in 2023 frame the typical range for FCF Margin.
The widest annual swing landed in 2023, when FCF Margin soared 18959 bps; it then tumbled 9551468 bps in 2024.
A 4-year view of FCF Margin shows it stood at 170.09% in 2022, then plunged by 87 bps to 318.65% in 2023, then plunged by 29974 bps to 95833.33% in 2024, then soared by 100 bps to 31.57% in 2026.
Per Business Quant data, the three most recent FCF Margin figures were 31.57% in Q2 2026, 95833.33% in Q4 2024, and 1241.82% in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.78 Bn	131.92 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.56 Bn	78.57 Bn	3.93 Bn	13.35%
3	Argenx Se	65.48 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	59.12 Bn	53.98 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.75 Bn	28.45 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.72 Bn	668.28 Mn	41.07%
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.20 Bn	26.36 Bn	-	70.82%
10	Werewolf Therapeutics	44.20 Mn	44.20 Mn	-	31.57%

Download Data